Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
1,277.50
-6.10
(-0.48%)
At close: February 28 at 3:30:01 PM GMT+5:30
Breakdown
TTM
3/31/2024
3/31/2023
Operating Cash Flow
-1,072,110
-1,072,110
-1,627,650
Investing Cash Flow
5,105,450
5,105,450
-678,340
Financing Cash Flow
-3,905,440
-3,905,440
1,183,180
End Cash Position
222,640
222,640
94,740
Capital Expenditure
-637,670
-637,670
-439,950
Issuance of Capital Stock
--
--
5,647,580
Issuance of Debt
7,432,210
7,432,210
1,562,250
Repayment of Debt
-10,239,230
-10,239,230
-4,888,640
Free Cash Flow
-1,709,780
-1,709,780
-2,067,600
3/31/2023 - 1/24/2025
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
CONCORDBIO.NS Concord Biotech Limited
1,501.00
-5.56%
BCAX Bicara Therapeutics Inc.
13.30
+7.61%
RLYB Rallybio Corporation
0.7223
-2.39%
IMTX Immatics N.V.
4.3800
0.00%
ENSC Ensysce Biosciences, Inc.
5.39
+2.67%
PTGX Protagonist Therapeutics, Inc.
37.59
+3.44%
SION Sionna Therapeutics, Inc.
13.77
-6.71%
NKTR Nektar Therapeutics
0.8500
+6.76%
RIGL Rigel Pharmaceuticals, Inc.
23.06
+5.88%
ALLO Allogene Therapeutics, Inc.
1.9500
0.00%